Pipeline
Lead program:
Individualized Neoantigen Therapeutic Vaccines (INTV)
Other viral vector-based assets
Read our scientific presentations & publications
Key publications (5)
- PoxSTG-EEV: a Novel Enveloped Virion – Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery
J. Foloppe et al.
SITC 2026
– Abstract available on the SITC website – Download the Abstract– Download the Poster - Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties
A. Agaoua et al.
frontiers in Bioengineering and Biotechnology
– Article available on the frontiers website – Download the Article - A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial
C. Ottensmeier, et al.
Article available on Nature Communications website – Download the Article - Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms
- TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment
K. Bidet-Huang
World Vaccine Congress 2026 – Download the Oral Presentation
See all publications
Clinical trials FAQ
Important information
Please note that the Transgene drug candidates are currently only in the clinical testing phase, subject to regulations set by the competent authorities. Transgene is not legally authorized to decide on the eligibility of patients to be included in the clinical studies of which it is a sponsor. Only the investigating physicians responsible for the clinical study centers have the competence to decide whether a patient meets the inclusion and exclusion criteria with regard to the corresponding clinical study protocol. Please also note that Transgene cannot communicate or interact with patients on the progress or progress of the studies. You will find all publicly available information on clinicaltrials.gov.
Expanded access policy : Expanded Access | FDA
Clinicaltrial.gov: Home | ClinicalTrials.gov
What is a clinical trial?
Clinical trials are designed to evaluate new treatments, including their safety and efficacy. They are mandatory before approval and commercialization of new treatments.
Who can participate in a clinical trial?
Each clinical trial is conducted according to a protocol defined upstream and validated by the health authorities and various committees to protect the interest of patients. To be included in a clinical trial, the patient must meet a number of criteria that are specific to each trial and contained in the protocol.
Participate in a clinical study: what are the benefits and risks?
The risks and benefits of participating in a clinical trial are described in the research protocol and the informed consent document. The medical team also explains them to the patient, who is free to ask questions.
Participating in a clinical trial gives access to an innovative treatment before it is potentially widely available. Clinical trials also provide a specific frame of care and support, as well as an appropriate and rigorous follow-up during and after the completion of the treatment.
As with any treatment, drug candidates used in clinical trials can cause side effects. In some clinical trials, it is also possible to be part of the control group and not receive innovative treatment.
What is Transgene early access and compassionate use policy to investigational medicines?
Transgene’s position on Early Access to Investigational Medicines can be accessed here.
More information
More information on the website of the French National Cancer Institute (INCa) website or on the US National Cancer Institute website.
Expanded access policy: Access | FDA